Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

table to a $1.3 million decrease in ANA773 development costs partially offset by $0.5 million in severance costs recorded in conjunction with the strategic restructuring initiated in June 2009. ANA773 development costs during the second quarter of 2009 were primarily driven by the ongoing Phase I clinical trial for the treatment of hepatitis C. During the second quarter of 2008, ANA773 development costs were primarily driven by the now completed 13-week GLP animal toxicology studies and the Phase I oncology clinical trial. The ANA598 development costs during the second quarter of 2009 were primarily associated with the 14-day healthy volunteer study and the ongoing long-term chronic toxicology studies which were initiated in September 2008.

General and administrative expenses were $2.5 million for the second quarter of 2009, compared to $2.0 million for the second quarter of 2008. The $0.5 million increase primarily resulted from severance costs recorded in conjunction with the strategic restructuring initiated in June 2009.

Operating expenses were $7.2 million for the second quarter of 2009, compared to $7.5 million for the second quarter of 2008. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $1.1 million and $0.7 million for the second quarter of 2009 and 2008, respectively.

The net loss was $6.5 million for the second quarter of 2009, compared to a net loss of $7.1 million for the second quarter of 2008. Included in the net loss for the second quarter of 2009 is a $0.4 million gain resulting from a reduction between issuance and June 30, 2009 in the liability associated with common stock warrants issued in conjunction with the "registered direct" financing. Basic and diluted net loss per common share was $0.21 in the second quarter of 2009, compared to $0.25 in the second quarter of 2008. Non-cash share-based expense resulted in a $0.03 and $0.02 in
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Miles Holder, formerly of Micron ... Carbon Products team as Sales/Marketing Manager. Mr. Holder has ... service for the graphite industry. , “We are thrilled ... stated Dave Trinkley, VP of Market and Product Development ... experience in the graphite industry, along with his proven ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... , CHICAGO and HOBOKEN, N.J. , Aug. 2 ... of the Octapharma 25th Anniversary Grants Program is the Rush ... Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies ... , , ...
... August 2, 2010 INEOS Group has,today entered into a ... one of the world,s leading providers of research led,packaging to the global ... capabilities and,synergy,s of two leading global businesses. , ... INEOS Films is ...
... of the most fundamental processes in physics. Whether a ... summer due to the absorption of light quanta or ... diodes that convert electricity into light, we encounter the ... the interactions between individual light particles photons ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3One more step on the path to quantum computers 2
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
(Date:11/2/2014)... was fascinating to put a flashlight up to our ... Washington University in St. Louis engineers are using a ... to improve imaging of cancerous tissues and to develop ... K. Beare Distinguished Professor of Biomedical Engineering at the ... novel time-reversal technology that allows researchers to better focus ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Brandeis researchers, whose long-standing collaboration led to pioneering ... and its role in circadian rhythms, today were ... foremost international scientific honor. Michael Rosbash, the ... director of the Brandeis, National Center for Behavioral ...
... and Shenzhen, China - To facilitate the genomics ... genomics organization, University of Helsinki and Wuhan University, ... of Understanding (MOU) setting forth a framework for ... of genomics, such as archaeal organisms from hypersaline ...
... Each year the American Society of Plant Biologists (ASPB) ... a competitive process to attend the Plant Biology Annual ... Travel Award (WYITA) program is to increase attendance of ... independent scientist in academia, industry, or government at the ...
Cached Biology News:Brandeis scientists win prestigious prize for circadian rhythms research 2Brandeis scientists win prestigious prize for circadian rhythms research 3Brandeis scientists win prestigious prize for circadian rhythms research 4American Society of Plant Biologists honors early career women scientists 2
Form: Ready to use Applications: Western Blot, ELISA...
... Bench-Top Open System Chemistry Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical ... grating, diode spectrophotometer over 30 user-selectable wavelengths. ... ... ...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... the Flp-In System creates isogenic cell ... levels of the protein of interest. ... Figure 3 (click link below). In ... chloramphenicol-acetyl transferase (CAT) was subcloned into ...
Biology Products: